Heat Biologics, Inc. (HTBX) Shares Up 2.5%
Heat Biologics, Inc. (NASDAQ:HTBX) shares shot up 2.5% on Friday . The stock traded as high as $0.77 and last traded at $0.77. 706,969 shares changed hands during trading, an increase of 77% from the average session volume of 399,411 shares. The stock had previously closed at $0.75.
Several brokerages have recently weighed in on HTBX. Noble Financial reissued a “buy” rating on shares of Heat Biologics in a research report on Tuesday, July 4th. ValuEngine cut shares of Heat Biologics from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 13th. Zacks Investment Research cut shares of Heat Biologics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. Finally, Griffin Securities began coverage on shares of Heat Biologics in a research report on Tuesday, September 12th. They set a “buy” rating and a $2.25 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $2.13.
The stock’s market cap is $27.16 million. The firm’s 50-day moving average is $0.59 and its 200 day moving average is $0.65.
A number of institutional investors have recently bought and sold shares of HTBX. KCG Holdings Inc. increased its position in Heat Biologics by 35.3% during the 1st quarter. KCG Holdings Inc. now owns 175,769 shares of the biopharmaceutical company’s stock worth $156,000 after purchasing an additional 45,831 shares in the last quarter. Sabby Management LLC purchased a new stake in Heat Biologics during the 1st quarter worth about $2,176,000. Finally, Vanguard Group Inc. increased its position in Heat Biologics by 11.9% during the 2nd quarter. Vanguard Group Inc. now owns 661,388 shares of the biopharmaceutical company’s stock worth $403,000 after purchasing an additional 70,290 shares in the last quarter. Hedge funds and other institutional investors own 8.74% of the company’s stock.
Heat Biologics Company Profile
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
Receive News & Stock Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related stocks with our FREE daily email newsletter.